Decreased CDK2 activity and the increased presence of p21CIP1 in anti-CDK2 precipitates were consistently observed in multiple tumour cell lines subject to combined MET and CDK4 inhibition (Fig. 5a, c). The gene discussed is CDK2; the disease is neoplasm.